Scientists Explore a Muscle ‘Backup’ Protein in Promising Muscular Dystrophy Research

University of Pennsylvania researchers report encouraging results from a gene-editing strategy that helps muscle cells produce more of a naturally occurring “backup” protein. The findings come from mice, not a human clinical trial.

PHILADELPHIA, UNITED STATES — Scientists investigating Duchenne muscular dystrophy (DMD) have reported a promising experimental approach: instead of trying only to replace a missing muscle protein, they are finding ways to increase production of another protein that can perform some of its functions.

In a research update released on October 26, 2026, Penn Medicine described experiments using CRISPR gene editing to increase a protein called utrophin in mouse models of DMD. The treated animals showed encouraging signs of improved muscle performance and healthier muscle tissue. The findings offer a direction for further research, but they do not establish that the approach is safe or effective in people.

Why Duchenne muscular dystrophy is so challenging

DMD is a serious inherited condition in which muscles progressively weaken. It typically arises from changes in the gene responsible for making dystrophin, a protein that helps protect muscle fibers as they contract and move. Without sufficient functional dystrophin, muscles become more vulnerable to injury and damage.

Researchers have explored a range of approaches to treating DMD, but its genetic diversity and the challenge of delivering therapies throughout the body’s muscles make developing broadly effective treatments difficult.

Utrophin: the muscle’s potential backup

Utrophin is a naturally occurring protein related to dystrophin. Scientists have long been interested in whether increasing utrophin could help compensate when dystrophin is absent or insufficient.

The Penn research team, led by Tejvir S. Khurana, MD, PhD, explored methods to increase utrophin production using a CRISPR-based gene-editing approach. Rather than aiming solely to repair an individual mutation in the dystrophin gene, the researchers investigated a different biological pathway that might support muscle strength.

What the mouse experiments found

According to Penn Medicine, treated mice showed signs of increased muscle force and better resistance during contraction, alongside fewer muscle fibers displaying features associated with the disease.

The research involved experimental delivery approaches, including muscle-targeted viral vectors and messenger RNA carried by lipid nanoparticles. These are active areas of biomedical research, but they still require careful testing for effectiveness, targeting, durability and safety.

The researchers believe stronger utrophin production could potentially protect muscle tissue or help it recover. That possibility remains a research hypothesis rather than a demonstrated benefit for patients.

Why researchers are cautiously optimistic

A major potential advantage of the utrophin strategy is that it focuses on a backup protein rather than requiring the same genetic repair for every specific DMD mutation. If future research demonstrates reliable delivery and safety, this could inform approaches with broader relevance to people living with the condition.

But several major questions remain. Can researchers deliver enough gene-editing material to the muscles that need it? Can effects last? What are the risks of unintended edits, immune reactions or other complications? And, crucially, will findings in mice translate into meaningful improvements for humans?

Those questions cannot be answered by the current mouse experiments alone. Any clinical application would require additional preclinical work, regulatory review and human studies.

Progress through collaboration

The work draws on research in gene editing, muscle biology and delivery technologies. Penn Medicine highlighted contributions involving mRNA approaches associated with Nobel laureate Drew Weissman and lipid-nanoparticle delivery expertise from Michael Mitchell.

It also reflects a broader effort among researchers, clinicians and patient-focused organizations to seek better options for people affected by DMD and their families.

Hope grounded in evidence

Medical progress often happens through carefully tested steps rather than sudden breakthroughs that immediately reach hospitals. The new Penn findings are encouraging because they demonstrate a plausible biological strategy and measurable outcomes in an animal model.

For patients and families, it is essential to distinguish that scientific promise from treatment availability: this is not a cure, not a proven human therapy and not a reason to change existing medical care.

For NewsPositive, the positive development is the continued progress of researchers working to understand how muscle tissue can be protected — and the new avenues that responsible experimentation may open.

Primary source: Penn Medicine, “Stopping muscular dystrophy with a ‘backup’ protein,” October 26, 2026.

Editorial note: This article reports preclinical laboratory research in mice. It does not provide medical advice or describe an approved Duchenne muscular dystrophy treatment.